David Vitter on Stem Cell Research

Last Updated : Sep 09, 2010

Summary

Senator David Vitter supported the HOPE Act legislation, and voted against the Stem Cell Research Enhancement Act of 2007.

 

Voting Record

Hope Offered through Principled and Ethical Stem Cell Research

The final piece of legislation was dubbed the "HOPE" Act and was voted on the same day. The Hope Act (S30) shared many of the same parameters as the the Stem Cell Research Act, in that it mostly ensured that no new stem cells be created for the sole purpose of using them in research. The bill also ensured that no embryos be damaged in research. David Vitter voted in favor of the Hope Offered through Principled and Ethical Stem Cell Research.

David Vitter voted in favor of the Hope Offered through Principled and Ethical Stem Cell Research.

Stem Cell Research Enhancement Act of 2007

In April of 2007, two more stem cell related bills were voted on in the Senate. The Stem Cell Research Enhancement Act of 2007 (S5) passed with support from a vast majority of Democratic Senators and about 1/3 of the Republican Senators. The legislation required (among other things) that any research done on stem cells involve only those which already existed. David Vitter voted against the Stem Cell Research Enhancement Act of 2007

David Vitter voted against the Stem Cell Research Enhancement Act of 2007

Stem Cell Research Enhancement Act

In July of 2006, the Senate passed the Stem Cell Research Enhancement Act. This legislation would have allowed research on human embryonic stem cells created after President Bush's 2001 deadline. The measure passed the House and Senate, but was vetoed. It passed the Senate 63-37. David Vitter voted against the Stem Cell Research Enhancement Act.

David Vitter voted against the Stem Cell Research Enhancement Act.

Alternative Pluripotent Stem Cell Therapies Enhancement Act

In July of 2006, the Senate voted unanimously to pass the Alternative Pluripotent Stem Cell Therapies Enhancement Act S 2754. The bill required the Secretary of Health and Human Services to do the following three tasks: provide guidance concerning the next steps required for additional research; prioritize research with the greatest potential for near-term clinical benefit; and take into account techniques outlined by the President\'s Council on Bioethics and any other appropriate techniques and research. David Vitter voted in favor of the Alternative Pluripotent Stem Cell Therapies Enhancement Act

David Vitter voted in favor of the Alternative Pluripotent Stem Cell Therapies Enhancement Act

 

Sponsored and Cosponsored Legislation

Session-111; Bill Number-S 99; Ethical Stem Cell Research Tax Credit Act of 2009 - Prime Sponsor

Amends the Internal Revenue Code to allow a tax credit for 30% of qualified stem cell research expenses paid or incurred in a taxable year. Defines "qualified stem cell research expenses" as expenses for carrying out basic and applied research to develop techniques for the isolation, derivation, production, testing, and human clinical use of stem cells that may result in improved understanding of or treatments for diseases and other adverse health conditions. Prohibits a tax credit for any research expenses that may involve: (1) the creation of a human embryo for research purposes; (2) the destruction of or discarding of, or risk of injury to, a human embryo; or (3) the use of any stem cell for prohibited purposes.

User Comments